FDA warns online vendors selling misbranded weight-loss, diabetes drugs
Reuters
Published Feb 13, 2024 03:08PM ET
Updated Feb 14, 2024 05:05AM ET
(Reuters) - The U.S. Food and Drug Administration said on Tuesday it has sent warning letters to two online vendors for selling unapproved and misbranded versions of semaglutide and tirzepatide, the active ingredients in popular diabetes and weight-loss drugs.
The letters were issued earlier this month to Synthetix, which sells drugs on a website called Helix Chemical Supply, and US Chem Labs after the U.S. regulator conducted a review of their respective websites in October.
The FDA said it found evidence the companies' websites offer the products, labeled for "research use only", for sale in the United States accompanied by claims such as weight loss, reducing the risk of stroke, heart attack, treatment of Alzheimer's disease, among others.
The companies are required to notify the agency within 15 working days of the receipt of the letter, of the specific steps taken to address any violations.
US Chem Labs and Synthetix did not immediately respond to a Reuters request for comment.
Reuters could not find semaglutide and tirzepatide products on Helix, but found semaglutide products on US Chem Labs' website, as of Tuesday afternoon.
Semaglutide is an active ingredient in Novo Nordisk (NYSE:NVO)'s Wegovy and Ozempic, while Eli Lilly (NYSE:LLY)'s diabetes drug sold as Mounjaro and its recently approved weight-loss drug Zepbound use tirzepatide.
Novo and its biggest rival in the obesity drug market, Eli Lilly, sued several medical spas, weight-loss clinics and compounding pharmacies last year to stop them from selling products purporting to contain the active ingredients.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.